The following discussion and analysis of the results of operations and financial condition of the Company for the quarters ended June 30, 2022 and March 31, 2022, should be read in conjunction with the other sections of this Quarterly Report, including the Financial Statements and notes thereto of the Company included in this Quarterly Report. The various sections of this discussion contain forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties as well as other matters over which we have no control. See "Cautionary Note Regarding Forward-Looking Statements." Our actual results may differ materially. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.





Overview

NutraLife BioSciences, Inc., a Florida corporation ("us", "we" or "our") was formed as a limited liability company in the state of Florida on April 1, 2010, to engage in the development and distribution of nutritional and dietary oral spray products. On December 3, 2012, we converted from a Limited Liability Company to a Florida Corporation.

We manufacture and distribute oral spray nutritional and dietary products. Our distribution strategy includes selling to private label customers retailers, distributors, and consumers through retail outlets.

Six Months Ended June 30, 2022 and 2021

We had sales of $136,313 and $175,469 for the six months ended June 30, 2022 and 2021, respectively, or a 22.3% decrease.

Cost of sales was $127,790 compared to $132,284 for the six months ended June 30, 2022 and 2021, respectively, or a 3.4% decrease. This decrease is directly related to the decrease in sales and production volume resulting from the shutdowns and business disruptions from the pandemic. The Company also significantly increased its production labor force.

Gross margin was $8,523 and $43,185 for the six months ended June 30, 2022 and 2021, respectively, or an 80.3% decrease.

General and administrative expenses were $836,548 compared to $899,274 for the six months ended June 30, 2022 and 2021, respectively, or a 6.9% decrease. This decrease is primarily due to the disruptions in the Company's operations from the pandemic.





4

Stock based compensation was $390,515 and $2,394,514 for the six months ended June 30, 2022 and 2021, respectively, or a 83.7% decrease.

Finance costs were $660,580 compared to $1,260,378 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $599,798. This decrease is the result of recognizing the expenses related to warrants issued as compensation for debt conversion in the prior year.

We incurred a net loss of ($1,984,651) compared to ($4,311,757) for the six months ended June 30, 2022 and 2021, respectively.

Three Months Ended June 30, 2022 and 2021

We had sales of $55,835 and $39,096 for the three months ended June 30, 2022 and 2021, respectively, or 42.9% increase from the first quarter of 2021.

Cost of sales was $4,665 compared to $35,416 for the three months ended June 30, 2022 and 2021, respectively, or 86.8% decrease.

Gross profit was $51,170 and $3,680 for the three months ended June 30, 2022 and 2021, respectively, or 1,290.5% increase.

General and administrative expenses were $457,474 compared to $461,719 for the three months ended June 30, 2022 and 2021, respectively, a decrease of 0.9%. This decrease is primarily due to the disruptions in the Company's operations from the pandemic.

Stock based compensation was $174,975 and $200,000 for the three months ended June 30, 2022 and 2021, respectively, a decrease of $25,025.

Our finance costs were $305,197 compared to $1,140,450 for the three months ended June 30, 2022 and 2021 respectively, a decrease of $835,253.

We incurred a net loss of ($900,842) compared to ($1,810,471) for the three months ended June 30, 2022 and 2021 respectively.

Liquidity and Capital Resources

Historically, the Company's primary cash needs have been related to working capital items, which the Company has largely funded through our revenues, working capital, cash on hand, proceeds from lending and proceeds from the issuance of stock.

As of June 30, 2022, the Company had a cash balance of $51,802. Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management's potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels.

We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.





Cash Flow Activities

As of June 30, 2022, the Company had a cash balance of $51,802.





5






Operating Activities

Cash used in operating activities is net income adjusted for certain non-cash items and changes in certain assets and liabilities, such as those included in working capital.

For the first three months of 2022, the Company's operating activities used cash of $701,373, compared to the first quarter of 2021 which used cash of $629,456. For details of the operating cash flows refer to the condensed consolidated statements of cash flows in Part I - Financial Information.





Investing Activities

During the six months ended June 30, 2022, the Company's investing activities included the acquisition of a license for $500,000 and an investment of $225,000 for an aggregate of $725,000.





Financing Activities

During the six months ended June 30, 2022, we received proceeds of $1,110,000 for revenue share agreements, $223,750 form the issuance of debt, net of $86,500 for the repayment of debt and $9,646 for the payment of finance leases.

Critical Accounting Policies and Estimates

Our financial statements have been prepared in accordance with U.S. GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the amounts and disclosures in the financial statements. Our estimates are based on our historical experience, knowledge of current events and actions we may undertake in the future, and on various other factors that we believe are reasonable under the circumstances. Our critical accounting policies and estimates are described in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies" in our Annual Report on Form 10-K filed with the SEC on April 11, 2022. There were no material changes to our accounting policies during the six months ended June 30, 2022.

Recent Accounting Pronouncements

(See "Recently Issued Accounting Pronouncements" in Note 2 of Notes to the Condensed Consolidated Financial Statements.)

© Edgar Online, source Glimpses